Loading
A phase 1/2 trial of Zilovertamab vedotin in diffuse large b-cell lymphoma and burkitt lymphoma, run by Merck Sharp & Dohme LLC, now recruiting.
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) is a phase 1/2 interventional study registered as NCT06395103 by Merck Sharp & Dohme LLC, with 90 participants planned, started 2024-08-16 and due to reach its primary completion in 2029-03-31. Interventions recorded: Zilovertamab vedotin. Conditions listed: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Zilovertamab vedotin, Merck & Co. (MSD), Antibody-drug conjugate (ADC), Diffuse large B-cell lymphoma.
Shares Zilovertamab vedotin, Merck & Co. (MSD), Antibody-drug conjugate (ADC), Diffuse large B-cell lymphoma.
Shares Zilovertamab vedotin, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Zilovertamab vedotin, Merck & Co. (MSD), Antibody-drug conjugate (ADC), Diffuse large B-cell lymphoma.
Shares Zilovertamab vedotin, Merck & Co. (MSD), Antibody-drug conjugate (ADC), Diffuse large B-cell lymphoma.
Shares Zilovertamab vedotin, Merck & Co. (MSD).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/